CURE Pharmaceutical Welcomes Industry Veteran Richard Serbin to its Advisory Board

Print Friendly, PDF & Email

/UCW/ OXNARD, CA – CURE Pharmaceutical (OTC QB:CURR), a preeminent developer and manufacturer of advanced oral thin film for use in pharmaceutical, veterinary, and buccal and dermal over-the-counter applications, today announces the appointment of Richard Serbin to its Advisory Board.

“Richard has impressive and extensive experience as management, regulatory and intellectual property counsel and various operational roles throughout the pharmaceutical industry,” said Rob Davidson, CEO of CURE Pharmaceutical. “We are very fortunate to count him among our trusted advisors and look forward to the benefit he brings to CURE.”

Richard S. Serbin currently serves as the President of Corporate Development and in-house legal counsel at Life Science Institute, LLC. Mr. Serbin is a global strategy advisor and entrepreneur with credentials both in pharmacy and law, complemented by more than 40 years of service as an FDA regulatory attorney and patent attorney in the healthcare industry. Mr. Serbin is an expert in licensing medical extracts, compounds, and technologies. He is a pharmacist and patent attorney with more than 25 years of experience in the pharmaceutical industry and the investment community. Founder of Radius Scientific Corporation, he also served as chief executive officer of Optigenex Inc. and president of Bradley Pharmaceuticals, and in multiple capacities at Ortho Pharmaceuticals, a Johnson & Johnson subsidiary, Revlon and Schering-Plough. In addition, he served as a consultant to various pharmaceutical companies.

Mr. Serbin served on the Board of Directors of 16 US and international subsidiary companies for Johnson & Johnson, including Ethicon, Ortho, J&J Consumer Products, Pittman-Moore, Mc Neil, and J&J Development Corporation. He served as Director at Viropro, Rapid Nutrition Plc and Optigenex.

Mr. Serbin plays an active role in developing business strategy and joint venture contacts and in guiding Mazal Plant Pharmaceuticals Inc. in regulatory compliance and investor relations. He worked on multiple international acquisitions and strategic relationships, and sat on the Board of Directors of several of its international subsidiaries, including those in India, Hong Kong, Japan, Taiwan, Germany, and England. He has been head of its Business Advisory Board. In addition, for the last 10 years, Mr. Serbin has been a senior advisor to the Swedish American Life Science Summit (SALSS), held annually in Stockholm, Sweden.

He holds a BS and a B. Pharmacy from Rutgers University and Rutgers University College of Pharmacy, a J.D. degree from Seton Hall Law School and a Masters degree in Trade Regulations and Law from NYU Law School.

About CURE Pharmaceutical
Headquartered in Oxnard, CA, CURE Pharmaceutical has developed and manufactures the most advanced oral thin film (CureFilm™) on the market today supported by its in-house, industry-leading full service cGMP manufacturing facility. CureFilm is more stable and durable than other oral thin films, with the ability to augment the dissolution for the intended rate of release through the buccal or gastrointestinal system. The technology enables differentiation within large therapeutic categories and potentially improves patient compliance, through its patented application of creating multiple layers, and sub-encapsulation of the delivered compound, potentially improving onset of action, lowering dosing, and enhancing, efficacy thereby widening the therapeutic index. CURE Pharmaceutical is traded under the symbol CURR. For more information about CURE Pharmaceutical, please visit its website at

Forward-looking statements

This press release contains forward-looking statements, which are subject to a number of risks and uncertainties. All statements, other than statements of fact, including those statements with respect to the Company’s business development, are forward-looking statements. Forward-looking statements speak only as of the date made and are not guarantees of future performance. We undertake no obligation to publicly update or revise any forward-looking statements.

Jules Abraham
JQA Partners, Inc.
[email protected]

, , ,